This inventor holds 26 USPTO granted patents, plus 2 CIPO patents, primarily in Kappa Agonist Compounds. Top assignees: Adolor Corporation, Merck + Co., Inc., Other. Active years: 1982-2007.
Location History:
- Fanwood, NJ (US) (1982)
- Malvern, PA (US) (1993 - 2007)
Company Filing History:
23 out of 69 
2 out of 4,770 
1 out of 834,453 Years Active: 1982-2007
Areas of Expertise:
Title: Profile of Alan L. Maycock: Innovator in Kappa Opioid Research
Introduction: Alan L. Maycock is a noted inventor based in Malvern, PA, USA, recognized for his significant contributions to pharmaceutical innovations, particularly in the area of kappa opioid agonist compounds. With a remarkable portfolio of 26 patents, Maycock is committed to advancing the understanding and utility of these compounds in medical applications.
Latest Patents: Maycock's latest patents focus on kappa agonist compounds and their pharmaceutical formulations. These innovations encompass compositions that exhibit kappa opioid agonist activity and outline five distinct methods for utilizing these compounds as both analgesics and treatments for pruritus. The patents describe how administering an effective amount of a kappa opioid receptor agonist can help prevent or treat pruritus, showcasing the structure and applicability of formulae I, II, III, and IV.
Career Highlights: Throughout his career, Alan L. Maycock has worked with several prestigious companies, notably Adolor Corporation and Merck & Company, Inc. His roles at these organizations have enabled him to collaborate on groundbreaking research leading to substantial advancements in the pharmaceutical industry.
Collaborations: Maycock has actively collaborated with colleagues such as Virendra Kumar and Wei Yuan Zhang. These partnerships have contributed to the successful development and implementation of innovative pharmaceutical solutions impacting pain management and related therapeutic areas.
Conclusion: Alan L. Maycock remains an influential figure in the field of pharmaceutical innovation, particularly through his work on kappa opioid agonist compounds. His patents and collaborative efforts continue to pave the way for enhanced treatment options in analgesics and pruritic conditions, underscoring the importance of ongoing research in this vital area of healthcare.